BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Delaunoit T, Alberts SR, Sargent DJ, Green E, Goldberg RM, Krook J, Fuchs C, Ramanathan RK, Williamson SK, Morton RF. Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Ann Oncol. 2005;16:425-429. [PMID: 15677624 DOI: 10.1093/annonc/mdi092] [Cited by in Crossref: 117] [Cited by in F6Publishing: 93] [Article Influence: 6.9] [Reference Citation Analysis]
Number Citing Articles
1 Leite D, Kater FR. Conversion treatment of hepatic metastases of colon adenocarcinoma by bevacizumab and FOLFOX. Anticancer Drugs 2011;22 Suppl 2:S1-7. [PMID: 21768791 DOI: 10.1097/01.cad.0000398726.60837.27] [Reference Citation Analysis]
2 Dy GK, Krook JE, Green EM, Sargent DJ, Delaunoit T, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP. Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741. J Clin Oncol. 2007;25:3469-3474. [PMID: 17687151 DOI: 10.1200/jco.2007.10.7128] [Cited by in Crossref: 45] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
3 Mohammad WM, Martel G, Mimeault R, Fairfull-Smith RJ, Auer RC, Balaa FK. Evaluating agreement regarding the resectability of colorectal liver metastases: a national case-based survey of hepatic surgeons. HPB (Oxford). 2012;14:291-297. [PMID: 22487066 DOI: 10.1111/j.1477-2574.2012.00440.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
4 Popescu I, Alexandrescu ST. Surgical options for initially unresectable colorectal liver metastases. HPB Surg 2012;2012:454026. [PMID: 23082042 DOI: 10.1155/2012/454026] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
5 Benoist S, Nordlinger B. Neoadjuvant treatment before resection of liver metastases. Eur J Surg Oncol 2007;33 Suppl 2:S35-41. [PMID: 17981428 DOI: 10.1016/j.ejso.2007.09.022] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
6 Lv W, Zhang GQ, Jiao A, Zhao BC, Shi Y, Chen BM, Zhang JL. Chemotherapy Plus Cetuximab versus Chemotherapy Alone for Patients with KRAS Wild Type Unresectable Liver-Confined Metastases Colorectal Cancer: An Updated Meta-Analysis of RCTs. Gastroenterol Res Pract 2017;2017:8464905. [PMID: 28167959 DOI: 10.1155/2017/8464905] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
7 Song W, Hu P, Guo S, Hu J, Song C, Wang T, Gao Z, Yue T. Oxidative stress and endoplasmic reticulum stress contribute to L. paracasei subsp. paracasei M5L exopolysaccharide-induced apoptosis in HT-29 cells. Food Sci Nutr 2021;9:1676-87. [PMID: 33747478 DOI: 10.1002/fsn3.2142] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Abdel-Misih SR, Schmidt CR, Bloomston PM. Update and review of the multidisciplinary management of stage IV colorectal cancer with liver metastases. World J Surg Oncol 2009;7:72. [PMID: 19788748 DOI: 10.1186/1477-7819-7-72] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
9 Falcone A, Fornaro L, Loupakis F, Masi G, Vasile E. Optimal approach to potentially resectable liver metastases from colorectal cancer. Expert Rev Anticancer Ther. 2008;8:1533-1539. [PMID: 18925845 DOI: 10.1586/14737140.8.10.1533] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
10 Mandalà M, Mosconi S, Quadri A, Milesi L, Labianca R. Neoadjuvant chemotherapy for patients with liver metastases from colorectal cancer. Expert Rev Anticancer Ther. 2007;7:887-897. [PMID: 17555399 DOI: 10.1586/14737140.7.6.887] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
11 Haraldsdottir S, Wu C, Bloomston M, Goldberg RM. What is the optimal neo-adjuvant treatment for liver metastasis? Ther Adv Med Oncol. 2013;5:221-234. [PMID: 23858331 DOI: 10.1177/1758834013485111] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
12 Akiyoshi T, Fujimoto Y, Konishi T, Kuroyanagi H, Ueno M, Oya M, Miyata S, Yamaguchi T. Prognostic factors for survival after salvage surgery for locoregional recurrence of colon cancer. Am J Surg 2011;201:726-33. [PMID: 20864084 DOI: 10.1016/j.amjsurg.2010.03.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
13 Mcloughlin JM, Jensen EH, Malafa M. Resection of Colorectal Liver Metastases: Current Perspectives. Cancer Control 2017;13:32-41. [DOI: 10.1177/107327480601300105] [Cited by in Crossref: 56] [Cited by in F6Publishing: 49] [Article Influence: 11.2] [Reference Citation Analysis]
14 Gulec SA. Y-90 Radiomicrosphere Therapy for Colorectal Cancer Liver Metastases. Seminars in Nuclear Medicine 2016;46:126-34. [DOI: 10.1053/j.semnuclmed.2015.10.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
15 Kim GP, Erlichman C. Oxaliplatin in the treatment of colorectal cancer. Expert Opinion on Drug Metabolism & Toxicology 2007;3:281-94. [DOI: 10.1517/17425255.3.2.281] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
16 Okines A, Cunningham D. Current perspective: Bevacizumab in colorectal cancer – A time for reappraisal? European Journal of Cancer 2009;45:2452-61. [DOI: 10.1016/j.ejca.2009.06.028] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
17 Saif MW. Secondary hepatic resection as a therapeutic goal in advanced colorectal cancer. World J Gastroenterol 2009; 15(31): 3855-3864 [PMID: 19701965 DOI: 10.3748/wjg.15.3855] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
18 Zaniboni A, Torri V, Tinazzi A, Codignola C, Faggiuolo R, Sperti E. Neoadjuvant Oxaliplatin-based Chemotherapy for Liver Metastases from Colorectal Cancer. An Italian Survey. Tumori 2005;91:383-7. [DOI: 10.1177/030089160509100501] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
19 Goldberg RM, Sargent DJ, Morton RF, Green E, Sanoff HK, McLeod H, Buckner J. NCCTG Study N9741: leveraging learning from an NCI Cooperative Group phase III trial. Oncologist 2009;14:970-8. [PMID: 19828593 DOI: 10.1634/theoncologist.2009-0175] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
20 Townsend AR, Chong LC, Karapetis C, Price TJ. Selective internal radiation therapy for liver metastases from colorectal cancer. Cancer Treat Rev 2016;50:148-54. [PMID: 27690234 DOI: 10.1016/j.ctrv.2016.09.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
21 Lehmann K, Rickenbacher A, Weber A, Pestalozzi BC, Clavien P. Chemotherapy Before Liver Resection of Colorectal Metastases: Friend or Foe? Annals of Surgery 2012;255:237-47. [DOI: 10.1097/sla.0b013e3182356236] [Cited by in Crossref: 83] [Cited by in F6Publishing: 42] [Article Influence: 8.3] [Reference Citation Analysis]
22 Bathe OF, Ernst S, Sutherland FR, Dixon E, Butts C, Bigam D, Holland D, Porter GA, Koppel J, Dowden S. A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases. BMC Cancer. 2009;9:156. [PMID: 19457245 DOI: 10.1186/1471-2407-9-156] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
23 Voroney JP, Brock KK, Eccles C, Haider M, Dawson LA. Prospective comparison of computed tomography and magnetic resonance imaging for liver cancer delineation using deformable image registration. Int J Radiat Oncol Biol Phys 2006;66:780-91. [PMID: 17011453 DOI: 10.1016/j.ijrobp.2006.05.035] [Cited by in Crossref: 46] [Cited by in F6Publishing: 33] [Article Influence: 2.9] [Reference Citation Analysis]
24 Raoul JL, Van Laethem JL, Peeters M, Brezault C, Husseini F, Cals L, Nippgen J, Loos AH, Rougier P. Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study. BMC Cancer. 2009;9:112. [PMID: 19366444 DOI: 10.1186/1471-2407-9-112] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 2.3] [Reference Citation Analysis]
25 Gill S, Sargent DJ. Evolving end points for clinical trials in advanced colorectal cancer. Curr colorectal cancer rep 2009;5:135-9. [DOI: 10.1007/s11888-009-0020-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
26 Saab R, Furman WL. Epidemiology and management options for colorectal cancer in children. Paediatr Drugs 2008;10:177-92. [PMID: 18454570 DOI: 10.2165/00148581-200810030-00006] [Cited by in Crossref: 33] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
27 Zhu J, Lian P, Liu F, Xu Y, Xu J, Guan Z, Liang L, Wang M, Cai S, Zhang Z. Phase II trial of first-line chemoradiotherapy with intensity-modulated radiation therapy followed by chemotherapy for synchronous unresectable distant metastases rectal adenocarcinoma. Radiat Oncol 2013;8:10. [PMID: 23295152 DOI: 10.1186/1748-717X-8-10] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
28 Barugel ME, Vargas C, Krygier Waltier G. Metastatic colorectal cancer: recent advances in its clinical management. Expert Review of Anticancer Therapy 2014;9:1829-47. [DOI: 10.1586/era.09.143] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
29 Sanoff HK, Sargent DJ, Green EM, McLeod HL, Goldberg RM. Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial. J Clin Oncol 2009;27:4109-15. [PMID: 19636001 DOI: 10.1200/JCO.2009.21.9527] [Cited by in Crossref: 63] [Cited by in F6Publishing: 33] [Article Influence: 4.8] [Reference Citation Analysis]
30 Ishibashi K, Ishida H, Ohsawa T, Okada N, Kumamoto K, Haga N. Impact of hepatic lymph node metastasis on survival of patients with synchronous resectable or unresectable liver metastases of colorectal cancer. Tech Coloproctol 2013;17:51-7. [PMID: 22936589 DOI: 10.1007/s10151-012-0881-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
31 Ashley AC, Sargent DJ, Alberts SR, Grothey A, Campbell ME, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP. Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer. Cancer. 2007;110:670-677. [PMID: 17559146 DOI: 10.1002/cncr.22831] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
32 Takahashi S, Konishi M, Kinoshita T, Gotohda N, Kato Y, Saito N, Sugito M, Yoshino T. Predictors for early recurrence after hepatectomy for initially unresectable colorectal liver metastasis. J Gastrointest Surg. 2013;17:939-948. [PMID: 23400510 DOI: 10.1007/s11605-013-2162-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
33 Sun DS, Zhang JD, Li L, Dai Y, Yu JM, Shao ZY. Accelerated hyperfractionation field-involved re-irradiation combined with concurrent capecitabine chemotherapy for locally recurrent and irresectable rectal cancer. Br J Radiol 2012;85:259-64. [PMID: 21385917 DOI: 10.1259/bjr/28173562] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
34 Pak LM, Kemeny NE, Capanu M, Chou JF, Boucher T, Cercek A, Balachandran VP, Kingham TP, Allen PJ, DeMatteo RP. Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential. J Surg Oncol. 2018;117:634-643. [PMID: 29165816 DOI: 10.1002/jso.24898] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 5.4] [Reference Citation Analysis]
35 Mohammad WM, Balaa FK. Surgical management of colorectal liver metastases. Clin Colon Rectal Surg. 2009;22:225-232. [PMID: 21037813 DOI: 10.1055/s-0029-1242462.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
36 Patiyil S, Alberts SR. Metastatic colorectal cancer: Therapeutic options. Curr Treat Options in Oncol 2006;7:389-98. [DOI: 10.1007/s11864-006-0007-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
37 Ramos FJ, Tabernero J. Cetuximab and chemotherapy for patients with unresectable CRC liver metastasis: are we changing the natural course of the disease? Onkologie 2007;30:602-4. [PMID: 18063871 DOI: 10.1159/000110799] [Reference Citation Analysis]
38 Okines A, Puerto OD, Cunningham D, Chau I, Van Cutsem E, Saltz L, Cassidy J. Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer 2009;101:1033-8. [PMID: 19789532 DOI: 10.1038/sj.bjc.6605259] [Cited by in Crossref: 128] [Cited by in F6Publishing: 106] [Article Influence: 9.8] [Reference Citation Analysis]
39 Chong G, Cunningham D. Improving long-term outcomes for patients with liver metastases from colorectal cancer. J Clin Oncol. 2005;23:9063-9066. [PMID: 16301589 DOI: 10.1200/jco.2005.04.4669] [Cited by in Crossref: 37] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
40 van Kessel CS, Buckens CF, van den Bosch MA, van Leeuwen MS, van Hillegersberg R, Verkooijen HM. Preoperative imaging of colorectal liver metastases after neoadjuvant chemotherapy: a meta-analysis. Ann Surg Oncol. 2012;19:2805-2813. [PMID: 22396005 DOI: 10.1245/s10434-012-2300-z] [Cited by in Crossref: 109] [Cited by in F6Publishing: 82] [Article Influence: 10.9] [Reference Citation Analysis]
41 Gill S, Blackstock AW, Goldberg RM. Colorectal cancer. Mayo Clin Proc. 2007;82:114-129. [PMID: 17285793 DOI: 10.1016/S0025-6196(11)60974-9] [Cited by in Crossref: 43] [Cited by in F6Publishing: 1] [Article Influence: 2.9] [Reference Citation Analysis]
42 Rossi L, Vakiarou F, Zoratto F, Bianchi L, Papa A, Basso E, Verrico M, Lo Russo G, Evangelista S, Rinaldi G, Perrone-Congedi F, Spinelli GP, Stati V, Caruso D, Prete A, Tomao S. Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC). Cancer Manag Res. 2013;5:377-385. [PMID: 24399885 DOI: 10.2147/cmar.s47986] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
43 Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, Grothey A, Vauthey JN, Nagorney DM, McWilliams RR. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27:3677-3683. [PMID: 19470929 DOI: 10.1200/jco.2008.20.5278] [Cited by in Crossref: 819] [Cited by in F6Publishing: 381] [Article Influence: 63.0] [Reference Citation Analysis]
44 Bidard FC, Kiavue N, Ychou M, Cabel L, Stern MH, Madic J, Saliou A, Rampanou A, Decraene C, Bouché O, Rivoire M, Ghiringhelli F, Francois E, Guimbaud R, Mineur L, Khemissa-Akouz F, Mazard T, Moussata D, Proudhon C, Pierga JY, Stanbury T, Thézenas S, Mariani P. Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial. Cells 2019;8:E516. [PMID: 31142037 DOI: 10.3390/cells8060516] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 8.0] [Reference Citation Analysis]
45 O'Connell MJ, Campbell ME, Goldberg RM, Grothey A, Seitz JF, Benedetti JK, André T, Haller DG, Sargent DJ. Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set. J Clin Oncol 2008;26:2336-41. [PMID: 18467725 DOI: 10.1200/JCO.2007.15.8261] [Cited by in Crossref: 123] [Cited by in F6Publishing: 72] [Article Influence: 8.8] [Reference Citation Analysis]
46 Zhao R, Zhu J, Ji X, Cai J, Wan F, Li Q, Zhong B, Tucker S, Wang D. A phase II study of irinotecan and capecitabine for patients with unresectable liver-only metastases from colorectal cancer. Jpn J Clin Oncol 2010;40:10-6. [PMID: 19773270 DOI: 10.1093/jjco/hyp114] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
47 Ye LC, Liu TS, Ren L, Wei Y, Zhu DX, Zai SY, Ye QH, Yu Y, Xu B, Qin XY, Xu J. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol. 2013;31:1931-1938. [PMID: 23569301 DOI: 10.1200/jco.2012.44.8308] [Cited by in Crossref: 244] [Cited by in F6Publishing: 117] [Article Influence: 27.1] [Reference Citation Analysis]
48 Sirohi B, Shrikhande SV, Perakath B, Raghunandharao D, Julka PK, Lele V, Chaturvedi A, Nandakumar A, Ramadwar M, Bhatia V, Mittal R, Kaur T, Shukla DK, Rath GK. Indian Council of Medical Research consensus document for the management of colorectal cancer. Indian J Med Paediatr Oncol 2014;35:192-6. [PMID: 25336788 DOI: 10.4103/0971-5851.142031] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
49 Pozzo C, Barone C, Kemeny NE. Advances in neoadjuvant therapy for colorectal cancer with liver metastases. Cancer Treatment Reviews 2008;34:293-301. [DOI: 10.1016/j.ctrv.2008.01.004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
50 Lee RC, Kanhere H, Trochsler M, Broadbridge V, Maddern G, Price TJ. Pancreatic, periampullary and biliary cancer with liver metastases: Should we consider resection in selected cases? World J Gastrointest Oncol 2018; 10(8): 211-220 [PMID: 30147847 DOI: 10.4251/wjgo.v10.i8.211] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
51 Glover KY, Eng C. Current and emerging trends in the treatment of metastatic colorectal cancer. Hematology/Oncology Clinics of North America 2007;21:8-17. [DOI: 10.1016/s0889-8588(07)80005-0] [Reference Citation Analysis]
52 Itatani Y, Akiyoshi T, Kuroyanagi H, Yamakawa K, Noaki R, Konishi T, Fujimoto Y, Ueno M, Oya M, Suenaga M, Yamaguchi T. Total mesorectal excision of initially unresectable locally advanced rectal cancer infiltrating the pelvic wall after treatment with FOLFOX4 plus bevacizumab and preoperative chemoradiation: report of a case. Surg Today 2012;42:75-9. [PMID: 22075663 DOI: 10.1007/s00595-011-0004-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
53 Kelly H, Goldberg RM. Systemic Therapy for Metastatic Colorectal Cancer: Current Options, Current Evidence. JCO 2005;23:4553-60. [DOI: 10.1200/jco.2005.17.749] [Cited by in Crossref: 227] [Cited by in F6Publishing: 70] [Article Influence: 13.4] [Reference Citation Analysis]
54 Ng JK, Urbanski SJ, Mangat N, McKay A, Sutherland FR, Dixon E, Dowden S, Ernst S, Bathe OF. Colorectal liver metastases contract centripetally with a response to chemotherapy: a histomorphologic study. Cancer. 2008;112:362-371. [PMID: 18041069 DOI: 10.1002/cncr.23184] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 3.1] [Reference Citation Analysis]
55 Natarajan N, Shuster TD. New Agents, Combinations, and Opportunities in the Treatment of Advanced and Early-Stage Colon Cancer. Surgical Clinics of North America 2006;86:1023-43. [DOI: 10.1016/j.suc.2006.06.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
56 Khan K, Wale A, Brown G, Chau I. Colorectal cancer with liver metastases: Neoadjuvant chemotherapy, surgical resection first or palliation alone? World J Gastroenterol 2014; 20(35): 12391-12406 [PMID: 25253940 DOI: 10.3748/wjg.v20.i35.12391] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 26] [Article Influence: 4.4] [Reference Citation Analysis]
57 White RR, Jarnagin WR. The Role of Aggressive Regional Therapy for Colorectal Liver Metastases. Cancer Investigation 2009;25:458-63. [DOI: 10.1080/07357900701508561] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
58 Funaioli C, Pinto C, Di Fabio F, Santini D, Ceccarelli C, De Raffaele E, Fanti S, Castellucci P, Longobardi C, Buggi F, Martoni AA. 18FDG-PET Evaluation Correlates Better than CT with Pathological Response in a Metastatic Colon Cancer Patient Treated with Bevacizumab-Based Therapy. Tumori 2007;93:611-5. [DOI: 10.1177/030089160709300617] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
59 Field K, Lipton L. Metastatic colorectal cancer-past, progress and future. World J Gastroenterol 2007; 13(28): 3806-3815 [PMID: 17657834 DOI: 10.3748/wjg.v13.i28.3806] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 43] [Article Influence: 3.0] [Reference Citation Analysis]
60 Chan G, Chee CE. Perioperative Chemotherapy for Liver Metastasis of Colorectal Cancer. Cancers (Basel) 2020;12:E3535. [PMID: 33256170 DOI: 10.3390/cancers12123535] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
61 Adam R, Aloia T, Lévi F, Wicherts DA, de Haas RJ, Paule B, Bralet MP, Bouchahda M, Machover D, Ducreux M. Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol. 2007;25:4593-4602. [PMID: 17925554 DOI: 10.1200/jco.2007.10.8126] [Cited by in Crossref: 154] [Cited by in F6Publishing: 35] [Article Influence: 10.3] [Reference Citation Analysis]
62 Ryan DP. Nonsurgical Approaches to Colorectal Cancer. The Oncologist 2006;11:999-1002. [DOI: 10.1634/theoncologist.11-9-999] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
63 Chen W, Ghosh D, Raghunathan TE, Sargent DJ. A false-discovery-rate-based loss framework for selection of interactions. Stat Med 2008;27:2004-21. [PMID: 17979139 DOI: 10.1002/sim.3118] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
64 Rubbia-Brandt L, Giostra E, Brezault C, Roth AD, Andres A, Audard V, Sartoretti P, Dousset B, Majno PE, Soubrane O, Chaussade S, Mentha G, Terris B. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol. 2007;18:299-304. [PMID: 17060484 DOI: 10.1093/annonc/mdl386] [Cited by in Crossref: 332] [Cited by in F6Publishing: 291] [Article Influence: 20.8] [Reference Citation Analysis]
65 Kelly CM, Kemeny NE. Liver-directed therapy in metastatic colorectal cancer. Expert Rev Anticancer Ther. 2017;17:745-758. [PMID: 28636427 DOI: 10.1080/14737140.2017.1345629] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
66 Gill S, Blackstock AW, Goldberg RM. Colorectal cancer. Mayo Clin Proc 2007;82:114-29. [PMID: 17285793 DOI: 10.4065/82.1.114] [Cited by in Crossref: 5] [Cited by in F6Publishing: 23] [Article Influence: 0.3] [Reference Citation Analysis]
67 Abad A, Massutí B, Antón A, Vega M, Yuste AL, Marcuello E, Luis Manzano J, Alonso V, Carrato A, Martinez-villacampa M, Tabernero J, Aranda E, Rivera F, Díaz-rubio E; (on behalf of the Spanish Cooperative Group for Digestive Tumor Therapy (TTD)). Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study. Acta Oncologica 2009;47:286-92. [DOI: 10.1080/02841860701630259] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
68 Cui HG, Cao XF. Surgery-predominant combined treatment for colorectal cancer. Shijie Huaren Xiaohua Zazhi 2008; 16(16): 1774-1780 [DOI: 10.11569/wcjd.v16.i16.1774] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
69 Voorthuizen TV, van Gulik TM, Punt CJ. Defining resectability of colorectal liver metastases: how and why? Colorectal Cancer 2013;2:61-72. [DOI: 10.2217/crc.12.79] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
70 Kuehrer I. Multimodal treatment of metastatic colorectal cancer. Acta Chir Iugosl 2006;53:51-5. [PMID: 17139885 DOI: 10.2298/aci0602051k] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
71 Inoue Y, Miki C, Kusunoki M. Current directions in chemotherapy for colorectal cancer. J Gastroenterol 2006;41:821-31. [DOI: 10.1007/s00535-006-1873-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
72 Liu K, Wan J, Zhu J, Li G, Sun W, Shen L, Cai S, Gu W, Lian P, Zhang Z. Role of pelvic radiotherapy for locally advanced rectal cancer and synchronous unresectable distant metastases. Cancer/Radiothérapie 2016;20:805-10. [DOI: 10.1016/j.canrad.2016.06.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
73 Bilchik AJ, Poston G, Curley SA, Strasberg S, Saltz L, Adam R, Nordlinger B, Rougier P, Rosen LS. Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note. J Clin Oncol. 2005;23:9073-9078. [PMID: 16361615 DOI: 10.1200/jco.2005.03.2334] [Cited by in Crossref: 110] [Cited by in F6Publishing: 28] [Article Influence: 6.9] [Reference Citation Analysis]
74 Sineshaw HM, Robbins AS, Jemal A. Disparities in survival improvement for metastatic colorectal cancer by race/ethnicity and age in the United States. Cancer Causes Control 2014;25:419-23. [PMID: 24445597 DOI: 10.1007/s10552-014-0344-z] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
75 Neumann UP, Thelen A, Röcken C, Seehofer D, Bahra M, Riess H, Jonas S, Schmeding M, Pratschke J, Bova R, Neuhaus P. Nonresponse to pre-operative chemotherapy does not preclude long-term survival after liver resection in patients with colorectal liver metastases. Surgery 2009;146:52-9. [PMID: 19541010 DOI: 10.1016/j.surg.2009.02.004] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
76 Hillner BE, Schrag D, Sargent DJ, Fuchs CS, Goldberg RM. Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma. Cancer 2005;104:1871-84. [DOI: 10.1002/cncr.21411] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 1.7] [Reference Citation Analysis]
77 Mohammad WM, Balaa FK. Surgical management of colorectal liver metastases. Clin Colon Rectal Surg 2009;22:225-32. [PMID: 21037813 DOI: 10.1055/s-0029-1242462] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
78 Hale MD, Hayden JD, Grabsch HI. Tumour-microenvironment interactions: role of tumour stroma and proteins produced by cancer-associated fibroblasts in chemotherapy response. Cell Oncol (Dordr) 2013;36:95-112. [PMID: 23494412 DOI: 10.1007/s13402-013-0127-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.4] [Reference Citation Analysis]
79 Padmanabhan C, Nussbaum DP, D'Angelica M. Surgical Management of Colorectal Cancer Liver Metastases. Surg Oncol Clin N Am 2021;30:1-25. [PMID: 33220799 DOI: 10.1016/j.soc.2020.09.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
80 Ishida K, Uesugi N, Hasegawa Y, Sugimoto R, Takahara T, Otsuka K, Nitta H, Kawasaki T, Wakabayashi G, Sugai T. Proposal for novel histological findings of colorectal liver metastases with preoperative chemotherapy. Pathol Int 2015;65:367-73. [PMID: 25940915 DOI: 10.1111/pin.12300] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
81 Shiomi K, Naito M, Sato T, Nakamura T, Nakashima H, Naito M, Mikubo M, Matsui Y, Watanabe M, Satoh Y. Effect of adjuvant chemotherapy after pulmonary metastasectomy on the prognosis of colorectal cancer. Ann Med Surg (Lond) 2017;20:19-25. [PMID: 28702182 DOI: 10.1016/j.amsu.2017.06.026] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
82 Lou E, Peters KB, Sumrall AL, Desjardins A, Reardon DA, Lipp ES, Herndon JE 2nd, Coan A, Bailey L, Turner S, Friedman HS, Vredenburgh JJ. Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma. Cancer Med 2013;2:185-95. [PMID: 23634286 DOI: 10.1002/cam4.58] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
83 Masi G, Fornaro L, Caparello C, Falcone A. Liver metastases from colorectal cancer: how to best complement medical treatment with surgical approaches. Future Oncology 2011;7:1299-323. [DOI: 10.2217/fon.11.108] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
84 Aloysius MM, Zaitoun AM, Beckingham IJ, Neal KR, Aithal GP, Bessell EM, Lobo DN. The pathological response to neoadjuvant chemotherapy with FOLFOX-4 for colorectal liver metastases: a comparative study. Virchows Arch. 2007;451:943-948. [PMID: 17805566 DOI: 10.1007/s00428-007-0497-1] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]
85 Takahashi T, Shibata Y, Tojima Y, Tsuboi K, Sakamoto E, Kunieda K, Matsuoka H, Suzumura K, Sato M, Naganuma T, Sakamoto J, Morita S, Kondo K. Multicenter phase II study of modified FOLFOX6 as neoadjuvant chemotherapy for patients with unresectable liver-only metastases from colorectal cancer in Japan: ROOF study. Int J Clin Oncol 2013;18:335-42. [DOI: 10.1007/s10147-012-0382-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
86 Yamaguchi T, Matsumoto H, Yasutome M, Mori T, Takahashi K. Phase I/II study of irinotecan, UFT and leucovorin with hepatic arterial infusion using 5-FU in colorectal cancer patients with unresectable liver metastases. Cancer Chemother Pharmacol 2011;67:629-35. [DOI: 10.1007/s00280-010-1368-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
87 Sørbye H, Berglund Å, Magne Tveit K, Øgreid D, Hoff Wanderås E, Wentzel-larsen T, Dahl O, Glimelius B. Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer. Acta Oncologica 2009;46:982-8. [DOI: 10.1080/02841860701261568] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
88 Tsukioka T, Nishiyama N, Iwata T, Nagano K, Izumi N, Mizuguchi S, Morita R, Inoue K, Suehiro S. Pulmonary metastasis from colorectal carcinoma with hepatic metastasis. Gen Thorac Cardiovasc Surg 2007;55:455-60. [PMID: 18049853 DOI: 10.1007/s11748-007-0165-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
89 Power DG, Kemeny NE. Chemotherapy for the conversion of unresectable colorectal cancer liver metastases to resection. Crit Rev Oncol Hematol. 2011;79:251-264. [PMID: 20970353 DOI: 10.1016/j.critrevonc.2010.08.001] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 3.0] [Reference Citation Analysis]
90 D'Angelica MI, Correa-Gallego C, Paty PB, Cercek A, Gewirtz AN, Chou JF, Capanu M, Kingham TP, Fong Y, DeMatteo RP. Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes. Ann Surg. 2015;261:353-360. [PMID: 24646562 DOI: 10.1097/sla.0000000000000614] [Cited by in Crossref: 101] [Cited by in F6Publishing: 34] [Article Influence: 14.4] [Reference Citation Analysis]
91 Zhao B, Gabriel RA, Vaida F, Lopez NE, Eisenstein S, Clary BM. Predicting Overall Survival in Patients with Metastatic Rectal Cancer: a Machine Learning Approach. J Gastrointest Surg 2020;24:1165-72. [PMID: 31468331 DOI: 10.1007/s11605-019-04373-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
92 Nishina T, Takano Y, Denda T, Yasui H, Takeda K, Ura T, Esaki T, Okuyama Y, Kondo K, Takahashi Y, Sugiyama Y, Muro K. A phase II clinical study of mFOLFOX6 plus bevacizumab as first-line therapy for Japanese advanced/recurrent colorectal cancer patients. Jpn J Clin Oncol 2013;43:1080-6. [PMID: 23999770 DOI: 10.1093/jjco/hyt127] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
93 Gallagher DJ, Kemeny N. Improving Response and Outcomes for Patients With Liver-Limited Metastatic Colorectal Cancer. Clinical Colorectal Cancer 2010;9:S36-43. [DOI: 10.3816/ccc.2010.s.005] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
94 Townsend A, Price T, Karapetis C. Selective internal radiation therapy for liver metastases from colorectal cancer. Cochrane Database Syst Rev 2009;:CD007045. [PMID: 19821394 DOI: 10.1002/14651858.CD007045.pub2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
95 Correa-Gallego C, Gavane S, Grewal R, Cercek A, Klimstra DS, Gewirtz AN, Kingham TP, Fong Y, DeMatteo RP, Allen PJ, Jarnagin WR, Kemeny N, D'Angelica MI. Prospective evaluation of 18F-fluorodeoxyglucose positron emission tomography in patients receiving hepatic arterial and systemic chemotherapy for unresectable colorectal liver metastases. HPB (Oxford) 2015;17:644-50. [PMID: 26010778 DOI: 10.1111/hpb.12421] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
96 Davies JM, Goldberg RM. Optimum chemotherapy regimens for neoadjuvant therapy of hepatic colorectal metastases: Neoadjuvant Colorectal Liver Metastases. J Surg Oncol 2010;102:946-54. [DOI: 10.1002/jso.21653] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]